Targeting CD33+ acute myeloid leukemia with GLK-33, a lintuzumab-auristatin conjugate with a wide therapeutic window.
Satomaa T, Pynnönen H, Aitio O, Hiltunen JO, Pitkänen V, Lähteenmäki T, Kotiranta T, Heiskanen A, Hänninen AL, Niemelä R, Helin J, Kuusanmaki H, Vänttinen I, Rathod R, Nieminen AI, Yatkin E, Heckman CA, Kontro M, Saarinen J.
Satomaa T, et al. Among authors: heckman ca.
Mol Cancer Ther. 2024 Apr 2. doi: 10.1158/1535-7163.MCT-23-0720. Online ahead of print.
Mol Cancer Ther. 2024.
PMID: 38561023